Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.48 |
| ▸ | MET | P08581 | 10/20 | 0.45 |
| ▸ | IGF1R | P08069 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | MST1R | Q04912 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190648 | 0.92 | MET (0.48) | AXLMETIGF1RKDRINSR | |
| SCHEMBL680422 | 0.89 | MET (0.46) | AXLMETIGF1RKDRINSR | |
| SCHEMBL12190625 | 0.87 | MET (0.45) | AXLMETIGF1RKDRINSR | |
| SCHEMBL681116 | 0.84 | MET (0.44) | AXLMETIGF1RKDRINSR | |
| SCHEMBL680804 | 0.82 | MET (0.49) | AXLMETIGF1RKDRINSR | |
| SCHEMBL12190677 | 0.81 | AXL (0.54) | AXLMETKDRFLT3TYRO3 | |
| SCHEMBL680526 | 0.80 | AXL (0.57) | AXLMETTYRO3MERTK | |
| SCHEMBL680287 | 0.79 | AXL (0.52) | AXLMETKDRFLT3TYRO3 | |
| SCHEMBL680709 | 0.79 | AXL (0.58) | AXLMETKDRFLT3TYRO3 | |
| SCHEMBL680639 | 0.79 | AXL (0.52) | AXLMETKDRFLT3TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | AXL 113/4885MET 1/4885IGF1R 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.